We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+9.23%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.19B
AUM Growth
+$35.3M
Cap. Flow
+$22.8M
Cap. Flow %
0.54%
Top 10 Hldgs %
34.58%
Holding
124
New
4
Increased
47
Reduced
8
Closed
3

Top Buys

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$19.7M
2
RVMD icon
Revolution Medicines
RVMD
+$17.3M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$15.3M
4
PLRX icon
Pliant Therapeutics
PLRX
+$14M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$11.7M

Top Sells

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$58.6M
2
PEN icon
Penumbra
PEN
+$19.1M
3
IMCR icon
Immunocore
IMCR
+$18M
4
ALGN icon
Align Technology
ALGN
+$16.2M
5
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$13.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.08%
2 Consumer Staples 1.05%
3 Industrials 0.87%
4 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HUM icon
1
Humana
HUM
$43.7B
$207M 4.94%
426,500
– –
AGL icon
2
Agilon Health
AGL
$1.53B
$187M 4.47%
315,300
+400
+0.1% +$224K
PODD icon
3
Insulet
PODD
$11.5B
$171M 4.08%
536,750
+12,500
+2% +$3.71M
IMCR icon
4
Immunocore
IMCR
$1.72B
$148M 3.54%
3,001,662
-319,404
-10% -$18M
ARGX icon
5
argenx
ARGX
$53.4B
$130M 3.11%
350,000
– –
UNH icon
6
UnitedHealth
UNH
$376B
$128M 3.04%
270,000
– –
EVH icon
7
Evolent Health
EVH
$348M
$123M 2.94%
3,803,500
– –
NBIX icon
8
Neurocrine Biosciences
NBIX
$16.8B
$122M 2.92%
1,210,100
+87,600
+8% +$9.12M
PEN icon
9
Penumbra
PEN
$12.7B
$121M 2.88%
433,500
-74,750
-15% -$19.1M
RXDX
10
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$111M 2.64%
1,031,550
– –
IDXX icon
11
Idexx Laboratories
IDXX
$44.1B
$104M 2.48%
207,500
– –
BPMC
12
DELISTED
Blueprint Medicines
BPMC
$91.5M 2.18%
2,033,048
+141,538
+7% +$6.38M
KRTX
13
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$89.6M 2.14%
493,527
+79,765
+19% +$15.3M
MDGL icon
14
Madrigal Pharmaceuticals
MDGL
$10.8B
$84.3M 2.01%
348,121
– –
ALGN icon
15
Align Technology
ALGN
$12.1B
$82.6M 1.97%
247,350
-55,000
-18% -$16.2M
SGEN
16
DELISTED
Seagen Inc. Common Stock
SGEN
$81M 1.93%
400,200
– –
HZNP
17
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$80.8M 1.93%
740,100
+400
+0.1% +$44.2K
ISRG icon
18
Intuitive Surgical
ISRG
$127B
$76.3M 1.82%
298,500
– –
WST icon
19
West Pharmaceutical
WST
$24B
$70M 1.67%
202,000
+16,500
+9% +$4.82M
ALNY icon
20
Alnylam Pharmaceuticals
ALNY
$27.5B
$69.1M 1.65%
345,000
+12,500
+4% +$2.63M
EXAS
21
DELISTED
Exact Sciences
EXAS
$63.8M 1.52%
941,500
+54,000
+6% +$3.47M
ACHC icon
22
Acadia Healthcare
ACHC
$2.76B
$62.2M 1.48%
860,868
+15,368
+2% +$1.2M
CERE
23
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$61.3M 1.46%
2,513,916
+7,452
+0.3% +$219K
AGIO icon
24
Agios Pharmaceuticals
AGIO
$1.79B
$61.1M 1.46%
2,661,605
-334,987
-11% -$8.9M
SRPT icon
25
Sarepta Therapeutics
SRPT
$1.57B
$61M 1.46%
442,500
+6,500
+1% +$843K
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return

Rock Springs Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, Rock Springs Capital Management held 124 positions worth $4.19B, up 0.85% from $4.16B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Rock Springs Capital Management's Q1 2023 filing shows 4 new, 47 increased, 8 reduced and 3 closed positions. Its largest new stake was Mineralys Therapeutics: 1,167,492 shares worth $18.3M. The largest sale was Baxter International, an estimated $58.6M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q1 2023 buy was Mineralys Therapeutics: 1,167,492 shares worth $18.3M.
  • Rock Springs Capital Management added most to Karuna Therapeutics, Inc. Common Stock in Q1 2023, an estimated $15.3M increase.
  • Rock Springs Capital Management's biggest Q1 2023 reduction was Penumbra, cutting an estimated $19.1M.
  • Rock Springs Capital Management fully exited Baxter International in Q1 2023, selling an estimated $58.6M.
  • Rock Springs Capital Management's ten largest holdings make up 35% of its $4.19B portfolio in Q1 2023.
  • Rock Springs Capital Management opened 4 new positions and closed 3 in Q1 2023.
  • Rock Springs Capital Management's portfolio value rose 0.85% quarter-over-quarter to $4.19B.

Based on Rock Springs Capital Management's 13F filing for Q1 2023, filed 15 May 2023.